A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to use a study app on their phone to record and share information about all their injections of study medicine and to fill in questionnaires.

NCT Number	NCT05636176
Lead Sponsor	Novo Nordisk A/S
Conditions	Heart Failure
Enrollment	4,899 participants
Start Date	2023-05-08
Primary Completion	2027-07-02 (estimated)
Study Completion	2027-07-02 (estimated)
Updated on ClinicalTrials.gov	2026-07-07